ABILITY OF 2 PRETREATMENT RISK ASSESSMENT METHODS TO PREDICT PROSTATE CANCER RECURRENCE AFTER RADICAL PROSTATECTOMY: DATA FROM CaPSURE
Open Access
- 1 April 2005
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 173 (4) , 1126-1131
- https://doi.org/10.1097/01.ju.0000155535.25971.de
Abstract
Two methods widely used to predict the risk of treatment failure after radical prostatectomy for localized prostate cancer are the 3 level D’Amico risk classification and the Kattan nomogram. Although they have been previously validated, to our knowledge they have not been compared in a community based cohort. We tested the 2 instruments in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) database, a national registry of patients with prostate cancer, to assess their accuracy in a community based cohort. Men were invited to join CaPSURE from 33 American urology practices, of which 30 were community based. A total of 1,701 men with localized prostate cancer (T1-3a) were treated with radical prostatectomy between 1989 and 2000. Patients who received neoadjuvant or adjuvant therapy were excluded. Recurrence was defined as 2 or more consecutive prostate specific antigen measurements of 0.2 ng/ml or greater, or a second treatment greater than 6 months after surgery. Freedom from progression (FFP) was based on life table estimates and Kaplan-Meier curves. Risk groups were compared using a Cox proportional hazards model and ANOVA. Based on the D’Amico classification 671 cases (39%) were classified as low risk, 446 (26%) were intermediate risk and 584 (34%) were high risk. Five-year FFP was 78%, 63% and 60% in the low, intermediate and high risk groups (HR 1.00, 1.87 and 2.32 respectively, p <0.0001). Mean 5-year FFP predicted by the Kattan nomogram in the same risk groups was 91%, 74% and 69%, respectively. Outcomes in the low risk group were tightly grouped about the mean but there was considerable dispersion of outcomes in the intermediate (30% to 98% FFP) and high (17% to 98%) risk groups. Stratifying patients in CaPSURE into low, intermediate and high risk categories for disease as described by D’Amico or applying the Kattan nomogram resulted in statistically significant differences in predicted 5-year FFP. However, there was considerable overlap of outcomes between the intermediate and high risk groups. This analysis suggests that simply estimating disease recurrence by stratifying patients into low, intermediate and high risk groups may not provide sufficient information for predicting outcomes among individuals.Keywords
This publication has 15 references indexed in Scilit:
- THE CONTEMPORARY MANAGEMENT OF PROSTATE CANCER IN THE UNITED STATES: LESSONS FROM THE CANCER OF THE PROSTATE STRATEGIC UROLOGIC RESEARCH ENDEAVOR (CAPSURE), A NATIONAL DISEASE REGISTRYJournal of Urology, 2004
- Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomyPublished by Elsevier ,2003
- A validation of two preoperative nomograms predicting recurrence following radical prostatectomy in a cohort of European menUrologic Oncology: Seminars and Original Investigations, 2002
- Comparisons of nomograms and urologists' predictions in prostate cancerSeminars in Urologic Oncology, 2002
- Variations in Morbidity after Radical ProstatectomyNew England Journal of Medicine, 2002
- Impact of socioeconomic status and race on clinical parameters of patients undergoing radical prostatectomy in an equal access health care systemUrology, 2000
- Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate CancerJAMA, 1998
- A Preoperative Nomogram for Disease Recurrence Following Radical Prostatectomy for Prostate CancerJNCI Journal of the National Cancer Institute, 1998
- Combination of Prostate-Specific Antigen, Clinical Stage, and Gleason Score to Predict Pathological Stage of Localized Prostate CancerJAMA, 1997
- The capsure database: a methodology for clinical practice and research in prostate cancerUrology, 1996